ISIN / WKN | DE000A2P4LJ5 / A2P4LJ |
Ticker Symbol | PSG |
Type of Shares | Existing bearer shares with no-par value |
First day of trading | June 19, 2020 |
Number of Shares | 12,000,000 |
Stock Exchanges | Frankfurter Wertpapierbörse |
Designated Sponsor | Joh. Berenberg, Gossler & Co. KG, Neuer Jungfernstieg 20, 20354 Hamburg, Germany |
Paying Agent | Quirin Privatbank AG, Kurfürstendamm 119, 10711 Berlin, Germany |
PharmaSGP is a pure-play consumer health company with a broad portfolio of leading natural non-prescription pharmaceuticals sold over the counter (“OTC”) and other healthcare products. PharmaSGP’s products are mainly sold through pharmacies. Its products are based on natural active pharmaceutical ingredients with documented efficacy and few known side effects.
The Company’s core brands in the category „Health Brands“ cover chronic indications, including pain and other age-related ailments. In Germany, PharmaSGP is the market leader for systemic natural pain remedies with its brand families RubaXX® for rheumatic pain and Restaxil® for neuralgic pain. The DESEO® and Neradin® brands are aimed at the men’s health market. Since September 2021, the brands Baldriparan®, Formigran®, Spalt® and Kamol® are part of the PharmaSGP portfolio. With the No. 1* herbal sleep aid in Germany Baldriparan®, PharmaSGP expands its portfolio and enters the sleep disorder category. Formigran®, Spalt® and Kamol® expand the product range in the important category "pain therapy".
PharmaSGP has established an asset-light business model that ensures decidedly substantial scalability with a highly efficient cost structure. Years of in-depth regulatory experience make it possible to quickly integrate OTC products of the most diverse categories into the portfolio and launch onto markets. As a D2C specialist, PharmaSGP achieves a very wide coverage among relevant target groups with over 130 million contacts per month – and all this under attractive and efficient media conditions.
Drawing on these strengths, PharmaSGP has been generating continuous and profitable growth of the „Health Brands“ for many years.
PharmaSGP's growth strategy aims to make efficient use of the pan-European platform.
On the one hand, PharmaSGP is constantly expanding the number of indications covered by its product range, while on the other, PharmaSGP is pushing expansion within Europe. Apart from the further organic growth of the existing „Health Brands“, PharmaSGP will focus on the acquisition and integration of established brands in future.
The acquisition of the OTC brand portfolio (Baldriparan®, Formigran®, Spalt® and Kamol®) from the GlaxoSmithKline Group in September 2021 is part of the successful M&A strategy. Strategically, PharmaSGP is strengthening its business by further expanding the "Health Brands" category, extending the therapeutic areas and opening up new markets in Europe. In the future, the SGP Group will also be active in Switzerland, Hungary, Poland, the Czech Republic and Slovakia.
CEO
Peter Gerckens (born 1987) joined PharmaSGP Holding SE as a member of the Executive Board in 2024. Peter has been CEO of PharmaSGP since January 2025 and is responsible for the operational business and the development of the product pipeline with a focus on marketing, research and development, quality assurance and purchasing. Peter started his career in marketing at Procter & Gamble and soon moved to McKinsey's Munich office. There he advised clients on strategic and operational issues for over 8 years, focusing on the consumer goods industry, among others. Before joining SGP, Peter was Managing Director and shareholder of a medium-sized service company in Munich with over 100 employees. There, Peter was responsible for finance, marketing and several business units.
Peter is a business economist and holds a Bachelor's degree (B.A.) from the University of St. Gallen, a Master's degree (M.Sc.) from the London School of Economics as well as an MBA from Harvard Business School.
Further mandates: Wilh. Werhahn KG, Neuss
Michael Rudolf (born 1974) joined the FUTRUE Group in 2016 and has been CFO of PharmaSGP since 2017. Prior to joining PharmaSGP, Michael Rudolf has worked at McKinsey & Company, served as head of mergers & acquisitions, portfolio management and corporate projects at Verlagsgruppe Weltbild, and was responsible for investment and portfolio management for digital investments of the Media-Saturn Group. He is holding a Master’s Degree in Business Administration from the University of Mannheim, Germany.
Key financial data | 2017* | 2018* | 2019* | 2020* | 2021* | 2022* | 2023* | 9M 2023** | 9M 2024** |
---|---|---|---|---|---|---|---|---|---|
Revenues (€ million) | 53.1 | 60.6 | 62.6 | 63.2 | 65.3 | 85.8 | 101.1 | 75.7 | 88.6 |
Revenue growth (%)** | – | 14.2 | 3.3 | 1.1 | 3.3 | 31.3 | 17.8 | 18.3 | 17.0 |
adjusted EBITDA (€ million)**,*** | 15.7 | 19.9 | 22.8 | 17.0 | 19.4 | 28.2 | 34.1 | 24.7 | 27.0 |
adjusted EBITDA margin (% of revenues)**,*** | 29.7 | 32.9 | 36.5 | 26.9 | 29.7 | 32.9 | 33.7 | 32.7 | 30.5 |
adjusted EBIT (€ million)**,*** | 15.3 | 19.5 | 22.4 | 16.5 | 15.9 | 19.0 | 24.7 | 17.7 | 20.0 |
adjusted EBIT margin (% of revenues)**,*** | 28.9 | 32.3 | 35.8 | 26.1 | 24.3 | 22.1 | 24.4 | 23.4 | 22.6 |
Total shareholders' equity (€ million)**** | 73.7 | 84.4 | 95.6 | 11.5 | 22.2 | 31.1 | 39.8 | 36.6 | 36.9 |
Balance sheet total (€ million)**** | 84.1 | 92.0 | 103.7 | 24.9 | 115.3 | 129.1 | 131.3 | 131.5 | 129.5 |
Equity ratio (% of balance sheet total)** | 87.7 | 91.7 | 92.1 | 46.1 | 19.3 | 24.1 | 30.3 | 27.8 | 28.5 |
* Audited, unless indicated otherwise.
** Unaudited.
*** PharmaSGP adjusts costs, among other items, for the corporate and organizational structuring of the PharmaSGP Group as well as legal and consulting fees in connection with acquisitions.
**** as of 31 December or 30 September
15 April 2025: Publication preliminary results for the financial year 2024
30 April 2025: Publication Financial Statements 2024
15 May 2025: Publication preliminary results Q1 2025
28 May 2025: Publication Interim Statement Q1 2025
25 June 2025: Annual General Meeting
11 September 2025: Publication preliminary results H1 2025
25 September 2025: Publication Half-Year Financial Report H1 2025
13 November 2025: Publication preliminary results Q3 2025
27 November 2025: Publication Interim Statement Q3 2025
16 April 2024: Publication preliminary results for the financial year 2023
29 April 2024: Publication Financial Statements 2023
14 May 2024: Publication preliminary results Q1 2024
28 May 2024: Publication Interim Statement Q1 2024
26 June 2024: Annual General Meeting
12 September 2024: Publication preliminary results H1 2024
26 September 2024: Publication Half-Year Financial Report 2024
14 November 2024: Publication preliminary results Q3 2024
28 November 2024: Publication Interim Statement Q3 2024
Mar 13-16, 2023: Berenberg EU Opportunities Conference / DACH Day
Mar 15, 2023: Publication of preliminary annual financial statements 2022
Mar 29-31, 2023: Jefferies Pan-European Mid-Cap Conference 2023
Apr 27, 2023: Publication of annual financial statements 2022
May 10, 2023: Publication of preliminary figures Q1 2023
May 26, 2023: Publication of Quarterly Release Q1 2023
June 28, 2023: Annual General Meeting 2023
Sep 14, 2023: Publication of preliminary figures H1 2023
Sep 28, 2023: Publication of the 2023 half-year report
Sep, 2023: Berenberg and Goldman Sachs 12th German Corporate Conference
Nov 14, 2023: Publication of the preliminary figures Q3 2023
Nov 28, 2023: Publication of Quarterly Release Q3 2023
Mar 15, 2022: Publication of preliminary figures for the 2021 annual financial statements
Mar 16, 2022: Berenberg EU Opportunities Conference / DACH Day
Mar 29-31, 2022: Jefferies Pan-European Mid-Cap Conference
Apr 28, 2022: Publication of annual financial statements 2021
May 17, 2022: Publication of preliminary figures Q1 2022
May 18, 2022: PLATOW EURO FINANCE Small Cap Conference
May 31, 2022: Publication of Quarterly Release Q1 2022
June 15, 2022: Annual General Meeting 2022 (virtual)
Sep 1, 2022: Publication of preliminary figures H1 2022
Sep 15, 2022: Publication of the 2022 half-year report
Sep 20-21, 2022: Berenberg and Goldman Sachs Eleventh German Corporate Conference
Nov 16, 2022: Publication of preliminary figures Q3 2022
Nov 15-17, 2022: Jefferies London Healthcare Conference
Nov 28-30, 2022: Deutsches Eigenkapitalforum 2022
Nov 30, 2022: Publication of Quarterly Release Q3 2022
Apr 1, 2021: Jefferies Pan-European Mid-Cap Virtual Conference
May 18, 2021: Publication of preliminary figures Q1 2021
May 18, 2021: Berenberg US Conference 2021 (virtual)
June 24, 2021: Annual General Meeting 2021 (virtual)
Oct 7, 2021: Berenberg Madrid Seminar in Madrid
Dec 9, 2021: Berenberg European Conference
Dec 3, 2020: Berenberg European Conference 2020 (Bagshot, UK)